Track Xilio Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Xilio Therapeutics Inc. Common Stock XLO · Stock Open Xilio Therapeutics Inc. Common Stock in new tab

8.08 USD
EPS
-0.60
P/B
0.77
ROE
-55.03
Beta
-0.11
Target Price
18.00 USD
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
EPS-0.60
Book Value10.98
Price to Book0.77
Debt/Equity8.72
% Insiders25.982%
Growth
Revenue Growth1.31%
Estimates
Forward P/E-14.60
Forward EPS-0.58
Target Mean Price18.00

DCF valuation

Model fair value for Xilio Therapeutics Inc. Common Stock (XLO)
Result
Sign in to run the valuation for XLO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus Strong buy · mean target 18.00 USD (low 16.00, high 20.00) · as of 12 Nov 2026
Low 16.00
Mean 18.00
High 20.00
Price 8.08
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Xilio Therapeutics Inc. Common Stock Logo Xilio Therapeutics Inc. Common Stock Analysis (XLO)

United States Health Care Official Website Stock

Is Xilio Therapeutics Inc. Common Stock a good investment? Xilio Therapeutics Inc. Common Stock (XLO) is currently trading at 8.08 USD. Market analysts have a consensus price target of 18.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Xilio Therapeutics Inc. Common Stock is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -0.58.

Investor FAQ

Does Xilio Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Xilio Therapeutics Inc. Common Stock?

Xilio Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.60.

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
NMS (United States) XLO
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
March 16, 2026 1:14
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion